ReviewInvestigative and clinical urology2016
Can we use methylation markers as diagnostic and prognostic indicators for bladder cancer?
Review in Investigative and clinical urology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- PAX1 and SOX1 Gene Methylation as a Detection and Triage Method for Cervical Intraepithelial Neoplasia Diagnosis.Acta cytologica · 2024Article
- Altered Glycosylation in Progression and Management of Bladder Cancer.Molecules (Basel, Switzerland) · 2023Review
- Non-Invasive Disease Specific Biomarker Detection Using Infrared Spectroscopy: A Review.Molecules (Basel, Switzerland) · 2023Review
- Molecular Markers in Urinary Bladder Cancer: Applications for Diagnosis, Prognosis and Therapy.Veterinary sciences · 2022Review
- Towards reliable diagnostics of prostate cancer via breath.Scientific reports · 2021Article
- Epigenetically inactivated RASSF1A as a tumor biomarker.Bosnian journal of basic medical sciences · 2021Review
- Advances in urinary biomarker discovery in urological research.Investigative and clinical urology · 2020Review
- TAp73 expression and P1 promoter methylation, a potential marker for chemoresponsiveness to cisplatin therapy and survival in muscle-invasive bladder cancer (MIBC).Cell cycle (Georgetown, Tex.) · 2019Article
- Promoter methylation analysis ofOncoTargets and therapy · 2018Article
- Article
- Changing landscape of diagnosis and treatment of bladder cancer.Investigative and clinical urology · 2016Article
- Relationships betweenOncoTargets and therapy · 2016Article
- Urine IRF4/PENK/PXDN Methylation Signatures Enable Machine Learning-Driven Bladder Cancer Detection and Microenvironment Dissection.Technology in cancer research & treatmentArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Urothelial carcinomas of the urinary bladder have diverse biological and functional characteristics, and numerous factors are likely to be involved in recurrence, progression, and patient survival. While several molecular markers used to evaluate the development and prognosis of bladder cancer have been studied, they are of limited value; therefore, new molecular parameters useful for predicting the prognosis of bladder cancer patients (particularly patients at high risk of progression and recurrence) are required. Recent progress in the understanding of epigenetic modification and gene silencing has provided new opportunities for the detection, treatment, and prevention of cancer. Methylation is an important molecular mechanism in bladder cancer and may have utility as a prognostic and/or diagnostic marker. This review discusses the epigenetic issues involved in the detection and prediction of bladder cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.